Why IMU is a multi multi bagger, page-12542

neoPOLEM ... potentially our next attack on cancer

Nick Ede, Chief Technology Officer at IMU, has returned my email question regarding the potential neoPOLEM trial I mentioned in an earlier post.

The neoPOLEM trial could well begin later this year (2023). It is a trial in operable MSI high, colon and rectal cancer (CRC), as I suggested in the first post.

Of course, the market will be updated as preparations proceed throughout 2023.

But, here’s the kicker ... it was IMU that was approached, by a group of world-class gastrointestinal oncologists, to conduct the trial with our PD1-Vaxx. They must be impressed by the potential of our treatment or by what we are seeing in our trials.

As Nick rightly stated, ‘it’s a hot space for PD1 targeted therapies, with pembrolizumab just receiving approval just last week.”

Personally, I can’t think of any Ozzie bio-tech that is covering such a wide range of areas within the oncology space. I just love that we continue to see talented oncologists, from around the globe, ‘busting’ (my word) to work with IMU on so many potential treatments.

Of course, not investment advice so please seekappropriate professional advice when required.